Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan and Cyclophosphamide for BMT Conditioning in TBI-Ineligible Patients
NCT00002502Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 1992
- Primary completion
- May 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, cyclophosphamide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 1992; status: completed.
02
Drugs
busulfancyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00002502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002502.